Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.663986
Keywords
immune checkpoint inhibitor; pneumonitis; non-small-cell lung cancer; diagnosis; management
Categories
Ask authors/readers for more resources
Immunotherapy, specifically PD-1, PD-L1, and CTLA-4 inhibitors, has revolutionized the therapeutic strategy for various malignancies. However, immune-related adverse events such as checkpoint inhibitor pneumonitis (CIP) have become a significant concern, particularly in non-small cell lung cancer patients. The diagnosis and management of CIP in NSCLC patients may be more complicated due to overlapping respiratory symptoms caused by the primary tumor following immunotherapy.
Immunotherapy that includes programmed cell death-1 (PD-1), programmed cell death- ligand 1 (PD-L1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitors has revolutionized the therapeutic strategy in multiple malignancies. Although it has achieved significant breakthrough in advanced non-small cell lung cancer patients, immune-related adverse events (irAEs) including checkpoint inhibitor pneumonitis (CIP), are widely reported. As the particularly worrisome and potentially lethal form of irAEs, CIP should be attached more importance. Especially in non-small cell lung cancer (NSCLC) patients, the features of CIP may be more complicated on account of the overlapping respiratory signs compromised by primary tumor following immunotherapy. Herein, we included the previous relevant reports and comprehensively summarized the characteristics, diagnosis, and management of CIP. We also discussed the future direction of optimal steroid therapeutic schedule for patients with CIP in NSCLC based on the current evidence.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available